Search research articles
Contact Us
Filters
Showing results (481-490 of 627) with videos related to
Page
of 63
Sort By:
Circulation
|
December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts
Jonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal
|
October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial
Kenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
Journal of the American Society of Nephrology : JASN
|
October 25, 2023
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials
Robert A Fletcher, Niels Jongs, Glenn M Chertow, et al.
Journal of the American Heart Association
|
June 22, 2023
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
Robert A Fletcher, Clare Arnott, Patrick Rockenschaub, et al.
Journal of the American College of Cardiology
|
May 7, 2016
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial
Pascal Vranckx, Harvey D White, Zhen Huang, et al.
Journal of the American Heart Association
|
November 19, 2014
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial
David C Wheeler, Gerard M London, Patrick S Parfrey, et al.
Heart (British Cardiac Society)
|
June 8, 2018
Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation
Michael T Durheim, DaJuanicia N Holmes, Rosalia G Blanco, et al.
Heart (British Cardiac Society)
|
February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
Günter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Hemodialysis International. International Symposium on Home Hemodialysis
|
November 14, 2015
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial
Patrick H Pun, Safa Abdalla, Geoffrey A Block, et al.
Journal of the American Heart Association
|
April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial
Jonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Page
of 63
Search research articles
Search
Showing results (481-490 of 627) with videos related to
Sort By:
Page
of 63
Circulation
|
December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts
Jonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.
European Heart Journal
|
October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial
Kenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.
Journal of the American Society of Nephrology : JASN
|
October 25, 2023
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials
Robert A Fletcher, Niels Jongs, Glenn M Chertow, et al.
Journal of the American Heart Association
|
June 22, 2023
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
Robert A Fletcher, Clare Arnott, Patrick Rockenschaub, et al.
Journal of the American College of Cardiology
|
May 7, 2016
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial
Pascal Vranckx, Harvey D White, Zhen Huang, et al.
Journal of the American Heart Association
|
November 19, 2014
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial
David C Wheeler, Gerard M London, Patrick S Parfrey, et al.
Heart (British Cardiac Society)
|
June 8, 2018
Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation
Michael T Durheim, DaJuanicia N Holmes, Rosalia G Blanco, et al.
Heart (British Cardiac Society)
|
February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
Günter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Hemodialysis International. International Symposium on Home Hemodialysis
|
November 14, 2015
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial
Patrick H Pun, Safa Abdalla, Geoffrey A Block, et al.
Journal of the American Heart Association
|
April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial
Jonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Page
of 63